UVision, a young North Carolina biotechnology company, has filed to raise $2 million in equity, according to a filing with the Securities and Exchange Commission.

UVision 360 Inc. filed the Form D on Dec. 6 stating it has sold $716,427 of the total amount offered of $2 million. The company intends to use the money for working capital, which may include normal compensation to executive officers.

This Triangle-based company has developed a hysteroscopy system designed to allow more gynecological procedures to be performed in an office vs. hospital setting. It is raising capital to fund what its hope to be the final stages of its Food and Drug Administration approval process.

Chief Executive Officer Allison London Brown has extensive experience with start-ups and medical agencies.

Brown is a co-founder and board member of Aegis Women’s Health Technologies as well as a senior advisor for Galaxy Diagnostics Inc.

Brown is also managing director and founder of Allison London Brown Consulting, a consulting company for medical device and biotech start-up companies.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must first file what’s known as a Form D electronically with the SEC after they first sell their securities.

Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism.